Company intelligence / Profile preview

MBX Biosciences, Inc.

Carmel, Indiana, United Statesmbxbio.com ↗

Ownership: Public · MBX
Development stage: Phase 2

Overview

Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism with topline results expected in Q3 2025. MBX 1416 completed Phase 1 trials with Phase 2 for post-bariatric hypoglycemia expected to begin in 2H 2025. IND submission for MBX 4291 in obesity anticipated in Q2 2025.[4][9]

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Precision peptide therapiesPeptide prodrugs
Industry: Biotech

Drug pipeline

6 assets

canvuparatide

5 more assets in the full pipeline.

Request access →

Financials

Market cap: $2.9B
Total revenue: $0
Enterprise value: $2.5B

Beyond the preview

Go deeper on MBX Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBX Biosciences, Inc..

Explore the full profile